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Background
Ulcerative colitis is a chronic inflammatory disease of the colon for which current 
treatments are not universally effective. One additional treatment may be tofacitinib 
(CP-690,550), an oral inhibitor of Janus kinases 1, 2, and 3 with in vitro functional 
specificity for kinases 1 and 3 over kinase 2, which is expected to block signaling 
involving gamma chain–containing cytokines including interleukins 2, 4, 7, 9, 15, and 
21. These cytokines are integral to lymphocyte activation, function, and proliferation.
Methods
In a double-blind, placebo-controlled, phase 2 trial, we evaluated the efficacy of to-
facitinib in 194 adults with moderately to severely active ulcerative colitis. Patients 
were randomly assigned to receive tofacitinib at a dose of 0.5 mg, 3 mg, 10 mg, or 
15 mg or placebo twice daily for 8 weeks. The primary outcome was a clinical re-
sponse at 8 weeks, defined as an absolute decrease from baseline in the score on 
the Mayo scoring system for assessment of ulcerative colitis activity (possible score, 
0 to 12, with higher scores indicating more severe disease) of 3 or more and a relative 
decrease from baseline of 30% or more with an accompanying decrease in the rectal 
bleeding subscore of 1 point or more or an absolute rectal bleeding subscore of 0 or 1.
Results
The primary outcome, clinical response at 8 weeks, occurred in 32%, 48%, 61%, and 
78% of patients receiving tofacitinib at a dose of 0.5 mg (P = 0.39), 3 mg (P = 0.55), 
10 mg (P = 0.10), and 15 mg (P<0.001), respectively, as compared with 42% of pa-
tients receiving placebo. Clinical remission (defined as a Mayo score ≤2, with no 
subscore >1) at 8 weeks occurred in 13%, 33%, 48%, and 41% of patients receiving 
tofacitinib at a dose of 0.5 mg (P = 0.76), 3 mg (P = 0.01), 10 mg (P<0.001), and 15 mg 
(P<0.001), respectively, as compared with 10% of patients receiving placebo. There 
was a dose-dependent increase in both low-density and high-density lipoprotein cho-
lesterol. Three patients treated with tofacitinib had an absolute neutrophil count of 
less than 1500.
Conclusions
Patients with moderately to severely active ulcerative colitis treated with tofacitinib 
were more likely to have clinical response and remission than those receiving pla-
cebo. (Funded by Pfizer; ClinicalTrials.gov number, NCT00787202.)
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Ulcerative colitis is a chronic in-flammatory disease of the colon.1,2 Pa-tients have intermittent disease flares 
interspersed with periods of remission.3 Ulcerative 
colitis is treated with mesalamine, glucocorti-
coids, azathioprine, and anti–tumor necrosis factor 
(TNF) agents (infliximab and adalimumab).4-6 
These agents are not universally effective, and some 
have been associated with serious toxic effects.7 
Additional treatments are needed.
Tofacitinib (CP-690,550) is a selective oral in-
hibitor of the Janus kinase (JAK) family of ki-
nases, including JAK1 and JAK3, a tyrosine kinase 
that mediates signal-transduction activity involv-
ing the common gamma chain of the surface re-
ceptors for multiple cytokines, including interleu-
kins 2, 4, 7, 9, 15, and 21.8,9 These cytokines are 
integral to lymphocyte activation, function, and 
proliferation. In vitro, tofacitinib inhibits inter-
leukin-2–dependent differentiation of type 2 and 
type 17 helper T cells as well as lipopolysaccharide-
induced innate immune responses.10 In addition, 
the inhibition of JAK1 attenuates signaling by pro-
inflammatory cytokines, such as interleukin-6 and 
interferon-γ.11 At high exposure to tofacitinib in 
preclinical models, inhibition of erythropoietin 
signaling may occur by means of inhibition of 
JAK2 signaling.11
Blockade of a common signaling molecule used 
by six important cytokines should result in sup-
pression of both T and B cells while maintaining 
regulatory T-cell function.8-10,12 Although the 
importance of the JAK family in the pathogene-
sis of ulcerative colitis is unclear, tofacitinib has 
shown efficacy for prevention of organ allograft 
rejection13,14 and in the treatment of rheumatoid 
arthritis15-18 and psoriasis.19,20 We designed an 
8-week, placebo-controlled, dose-finding trial of 




The sponsor, Pfizer, helped to design the study and 
analyze the data. The principal academic investi-
gator also designed the study and wrote the first 
draft of the manuscript. Data were collected by a 
contract research organization (Kendle Interna-
tional). All authors vouch for the veracity and com-
pleteness of the data and data analyses and for 
the fidelity of this report to the protocol (avail-
able with the full text of this article at NEJM.org), 
approved the final version, and made the decision 
to submit the manuscript for publication. All au-
thors have confidentiality agreements with Pfizer.
The study was approved by the institutional re-
view board or independent ethics committee for 
each center. All patients provided written informed 
consent.
Study Patients
Our 8-week multicenter, randomized, double-blind, 
placebo-controlled trial was conducted at 51 cen-
ters in 17 countries (Belgium, Brazil, Chile, Czech 
Republic, Denmark, France, Hungary, Israel, Italy, 
Mexico, the Netherlands, Poland, Slovakia, South 
Africa, Spain, Sweden, and the United Kingdom) 
from January 2009 through September 2010.
Two eligibility criteria were an age of at least 
18 years and a confirmed diagnosis of ulcerative 
colitis for at least 3 months. The other two eligi-
bility criteria relate to the Mayo scoring system 
for assessment of ulcerative colitis activity (in 
which scores range from 0 to 12 and higher 
scores indicate more severe disease),21 a scale 
composed of four subscores (for stool frequency, 
rectal bleeding, endoscopic findings, and Physi-
cian’s Global Assessment; scores on each can 
range from 0 to 3). These criteria were a score of 6 
to 12 on the Mayo scale and moderately or se-
verely active disease on sigmoidoscopy (i.e., a  Mayo 
endoscopic findings subscore of 2 or 3, respec-
tively). Patients could receive oral mesalamine or 
oral prednisone at a stable dose of 30 mg or less 
per day. Exclusion criteria are given in the Sup-
plementary Appendix (available at NEJM.org).
Study Design
Patients were randomly assigned, in a 2:2:2:3:3 ra-
tio, to receive oral tofacitinib (CP-690,550) (Pfizer) 
at a dose of 0.5 mg, 3 mg, 10 mg, or 15 mg or 
placebo, administered twice daily. Patients were 
treated for 8 weeks and followed for 4 weeks af-
terward (through 12 weeks). No data on clinical 
outcomes or adverse events were collected beyond 
12 weeks. Randomization was performed central-
ly, according to a computer-generated random-
ization schedule, with the use of permuted blocks 
balanced within each randomization stratum (e.g., 
previous exposure to anti-TNF therapy: yes or no). 
Oral mesalamine, if in use, was permitted at stable 
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doses; doses of oral glucocorticoids could not be 
increased, but tapering was permitted.
Follow-up, Efficacy, and Safety Evaluations
The Mayo score was determined at baseline and 
8 weeks. A partial Mayo score (based on three of 
the four questions [lacking the endoscopic find-
ings subscore], for a range of 0 to 9), was deter-
mined at 0, 2, 4, and 8 weeks. Colonoscopy or 
flexible sigmoidoscopy was performed at base-
line and again at 8 weeks. Clinical response was 
defined as a decrease from baseline in the total 
Mayo score — defined as an absolute decrease by 
at least 3 points and a relative decrease by at least 
30% — with an accompanying decrease in the 
rectal bleeding subscore of at least 1 point or an 
absolute rectal bleeding subscore of 0 or 1.22,23 
Clinical remission was defined as a total Mayo 
score of 0 to 2, with no individual subscore ex-
ceeding 1.22,23 Endoscopic response was defined 
as a decrease from baseline in the endoscopy sub-
score by at least 1, and endoscopic remission was 
defined as an endoscopy subscore of 0.22,23 The 
health-related quality of life was measured with 
the use of the Inflammatory Bowel Disease Ques-
tionnaire (with scores ranging from 0 to 224 points 
and scores of 170 points or more indicating clin-
ically inactive disease).24
Adverse events and use of medications con-
comitantly with tofacitinib or placebo were re-
corded through 12 weeks. Blood samples were 
collected at each visit for hematologic and chemi-
cal analyses; at 0, 4, and 8 weeks for measuring 
C-reactive protein (CRP) concentration; and at 
0, 8, and 12 weeks for lipid profiling. Stool sam-
ples were collected at each visit to ascertain fecal 
calprotectin concentrations (at Quintiles Labora-
tories; lower limit of detection, 28 mg per kilo-
gram of stool). Fecal calprotectin is a biomarker 
for neutrophil migration into the gastrointestinal 
tract and intestinal inflammation.
Statistical Analysis
The primary efficacy end point was a clinical re-
sponse at 8 weeks. Secondary efficacy end points 
included clinical remission at 8 weeks; endoscop-
ic response at 8 weeks; endoscopic remission at 
8 weeks; change from baseline in the partial Mayo 
score at 2, 4, and 8 weeks; change from baseline 
in the total Mayo score at 8 weeks; change from 
baseline in the CRP concentration at 4 and 8 weeks; 
and the change from baseline in the fecal calpro-
tectin concentration at 2, 4, and 8 weeks. The 
changes from baseline in low-density lipoprotein 
(LDL) and high-density lipoprotein (HDL) choles-
terol concentrations and serum creatinine concen-
trations at 8 and 12 weeks were also determined.
Prespecified Analyses
The analysis of the primary end point of clinical 
response at 8 weeks and the secondary end points 
of clinical remission, endoscopic response, and 
endoscopic remission — all at 8 weeks — was per-
formed by means of a maximum-effective-dose 
(Emax) model (or an alternative if appropriate) with 
treatment group as a factor and a term included 
for prior anti-TNF therapy. Patients with data miss-
ing for reasons other than insufficient response 
to therapy or an adverse event related to ulcer-
ative colitis were excluded from the analysis.
The change from baseline in the partial Mayo 
score at weeks 2, 4, and 8 and in the total Mayo 
score at 8 weeks were analyzed by means of an 
analysis-of-covariance model with terms for study 
treatment, baseline Mayo scores, and prior anti-
TNF treatment based on last-observation-carried-
forward imputation. CRP concentrations and 
fecal calprotectin concentrations were natural 
log–transformed, and the change from baseline 
at 2 weeks (for fecal calprotectin only) and 4 and 
8 weeks were analyzed with the use of an analysis-
of-variance model with last-observation-carried-
forward imputation. The changes from baseline in 
serum creatinine concentrations at 2, 4, 8, and 
12 weeks and in LDL and HDL cholesterol con-
centrations at 8 and 12 weeks were plotted and 
summarized according to dose to visually assess 
dose-related changes.
Post Hoc Analyses
Demographic and baseline characteristics were 
compared among treatment groups with the use 
of the chi-square test or Fisher’s exact test for 
categorical variables and analysis of variance with 
van der Waerden normal scores for continuous 
variables.
The prespecified analysis of the primary end 
point and related efficacy end points was the as-
sessment of dose response with the use of an Emax 
model. Here we report between-group compari-
sons; thus, we used the Cochran–Mantel–Haenszel 
chi-square test with stratification according to 
prior anti-TNF therapy. This analysis was based on 
data for all patients receiving at least one dose 
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of study medication. Patients with missing data 
were considered to be nonresponders. No adjust-
ments were made for multiple comparisons. A 
sensitivity analysis was conducted for clinical 
response, in which patients receiving placebo 
withdrawn for reasons not related to treatment 
were considered to be responders in a “worst-
case-scenario” approach.
To compare the consistency of the effect of 
study treatment on clinical response with placebo 
and with tofacitinib at a dose of 0.5 mg, 3 mg, 
10 mg, or 15 mg twice daily, we performed one 
prespecified subgroup analysis (according to pri-
or use or nonuse of anti-TNF therapy) as well as 
multiple post hoc subgroup analyses (according 
to sex, age, weight, body-mass index, duration of 
ulcerative colitis, colonic area involved, baseline 
total Mayo score, CRP concentration at baseline, 
baseline fecal calprotectin concentration, and 
glucocorticoid and mesalamine use at baseline) 
were performed. The heterogeneity of treatment 
effect was assessed with the use of a Breslow–
Day test. The incidence of adverse events was 
analyzed by means of Fisher’s exact test.
We calculated that a total of 180 patients 
would need to be enrolled and have data that 
could be evaluated in order for the study to have 
80% power to detect a relative difference of 20% 
in the rate of the primary end point of clinical 
response at 8 weeks between the group receiving 
placebo — assuming a rate of 35% in this group 
— and the group receiving tofacitinib at a dose 
of 15 mg twice daily, at the one-sided 5% sig-
nificance level. This calculation was based on a 
simulation study in which the simulated data were 
analyzed using a three-parameter Emax model. 
On this basis, we aimed to enroll 45 patients in 
the placebo group and in the 15-mg twice-daily 
tofacitinib group and 30 patients in each of the 
other tofacitinib groups (receiving 0.5 mg, 3 mg, 
and 10 mg twice daily).
R esult s
Patient Characteristics
A total of 195 patients were randomly assigned to 
a study group, of whom 194 received a dose of 
the study drug: 48 patients in the placebo group 
and 31, 33, 33, and 49 in the tofacitinib groups 
receiving 0.5 mg, 3 mg, 10 mg, and 15 mg twice 
daily, respectively. One patient in the placebo group 
did not receive the study drug and was excluded 
from the analyses. The demographic and base-
line disease characteristics were similar across the 
five groups (Table 1), with significant differences 
(P<0.05) only in glucocorticoid use at baseline. A 
total of 157 of the 194 patients (80.9%) complet-
ed the 8-week trial (Fig. 1 in the Supplementary 
Appendix). Concomitant drug therapy was used 
in 46, 31, 33, 32, and 47 patients in the placebo 
group and the 0.5-mg, 3-mg, 10-mg, and 15-mg 
tofacitinib groups, respectively. Across all treat-
ment groups, 131 (67.5%) patients received con-
comitant aminosalicylates and 85 (43.8%) received 




A clinical response at 8 weeks occurred in 20 of 
48 patients (42%) receiving placebo (95% confi-
dence interval [CI], 28 to 56), as compared with 
10 of 31 (32%) receiving 0.5 mg of tofacitinib 
(95% CI, 16 to 49; P = 0.39), 16 of 33 (48%) receiv-
ing 3 mg of tofacitinib (95% CI, 31 to 66; P = 0.55), 
20 of 33 (61%) receiving 10 mg of tofacitinib 
(95% CI, 44 to 77; P = 0.10), and 38 of 49 (78%) 
receiving 15 mg of tofacitinib (95% CI, 66 to 89; 
P<0.001) (Fig. 1A). The results of the prespecified 
statistical analysis for the clinical response (Ta-
ble 2 in the Supplementary Appendix) and the 
sensitivity analysis for clinical response (Fig. 2 in 
the Supplementary Appendix) are consistent with 
these findings. The efficacy of tofacitinib at dos-
es of 10 mg and 15 mg twice daily was generally 
consistent among demographic subgroups and 
subgroups according to baseline disease charac-
teristics; however, caution should be used in the 
interpretation of subgroup analyses owing to the 
limitations of multiple comparisons and small 
sample sizes (Fig. 4A and 4B in the Supplemen-
tary Appendix).
Secondary End Points
Clinical remission at 8 weeks occurred in 5 of 48 
patients (10%) receiving placebo (95% CI, 2 to 19), 
as compared with 4 of 31 (13%) receiving 0.5 mg 
of tofacitinib (95% CI, 1 to 25; P = 0.76), 11 of 33 
(33%) receiving 3 mg of tofacitinib (95% CI, 17 to 
49; P = 0.01), 16 of 33 (48%) receiving 10 mg of 
tofacitinib (95% CI, 31 to 66; P<0.001), and 20 of 
49 (41%) receiving 15 mg of tofacitinib (95% CI, 
27 to 55; P<0.001) (Fig. 1B).
An endoscopic response at 8 weeks occurred 
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in 22 of 48 patients (46%) receiving placebo, as 
compared with 16 of 31 (52%) receiving 0.5 mg 
of tofacitinib (P = 0.64), 19 of 33 (58%) receiving 
3 mg of tofacitinib (P = 0.30), 22 of 33 (67%) re-
ceiving 10 mg of tofacitinib (P = 0.07), and 38 of 
49 (78%) receiving 15 mg of tofacitinib (P = 0.001) 
Table 1. Demographic and Baseline Disease Characteristics, According to Study Group.*
Characteristic
Placebo 









Male sex — no. (%) 23 (48) 17 (55) 19 (58) 21 (64) 26 (53) 0.71
White race — no. (%)‡ 43 (90) 28 (90) 30 (91) 30 (91) 45 (92) 1.00
Age — yr 42.5±14.7 43.8±13.4 42.5±14.3 43.2±12.8 41.2±13.5 0.92
Body weight — kg 74.6±15.8 75.6±13.3 73.8±16.4 75.9±13.2 74.1±17.7 0.89
Body-mass index§ 25.3±4.0 26.3±3.7 24.8±3.9 25.4±4.0 25.6±5.2 0.61
Smoking status — no./total no. (%) 0.52
Never smoker 34/48 (71) 16/31 (52) 19/33 (58) 24/32 (75) 34/49 (69)
Smoker 2/48 (4) 3/31 (10) 4/33 (12) 1/32 (3) 4/49 (8)
Former smoker 12/48 (25) 12/31 (39) 10/33 (30) 7/32 (22) 11/49 (22)
Disease duration — yr 8.8±5.4 8.8±9.1 8.9±8.8 10.9±6.6 7.6±5.7 0.47
Involved colonic area — no./total no. (%) 0.56
Rectosigmoid 14/46 (30) 13/30 (43) 9/32 (28) 7/31 (23) 18/46 (39)
Left-sided 12/46 (26) 8/30 (27) 11/32 (34) 11/31 (35) 11/46 (24)
Extensive 20/46 (43) 9/30 (30) 12/32 (38) 13/31 (42) 17/46 (37)
CRP (mg/liter)¶ 0.66
Mean ±SD 9.7±12.8 18.8±29.4 12.6±13.2 11.3±16.5 17.1±26.4
Range 0.2–61.2 0.4–118.0 0.2–55.5 0.2–72.4 0.2–124.0
Elevated CRP — no./total no. (%)¶ 34/48 (71) 21/31 (68) 22/33 (67) 22/32 (69) 34/49 (69) 0.99
Fecal calprotectin (mg/kg)
Mean ±SD 1733±2596 1440±1623 1474±2182 1145±2001 1523±2575 0.49
Range 28–10,617 28–5919 28–9134 28–10,485 28–13,590
Mayo score‖ 8.2±1.6 8.6±1.6 8.3±1.5 8.0±1.7 8.0±1.5 0.38
Mesalamine use at baseline — no. (%) 29 (60) 16 (52) 19 (58) 25 (76) 33 (67) 0.29
Glucocorticoid use at baseline — no. (%) 13 (27) 11 (35) 10 (30) 19 (58) 13 (27) 0.03
Glucocorticoid failure within  
previous 12 mo — no. (%)
15 (31) 12 (39) 8 (24) 5 (15) 13 (27) 0.28
Anti-TNF exposure — no. (%) 15 (31) 9 (29) 10 (30) 10 (30) 15 (31) 0.81
Anti-TNF failure within previous  
12 mo — no. (%)
12 (25) 2 (6) 6 (18) 6 (18) 10 (20) 0.35
Immunosuppressant failure within  
previous 12 mo — no. (%)**
20 (42) 13 (42) 12 (36) 16 (48) 18 (37) 0.84
* Plus–minus values are means ±SD. CRP denotes C-reactive protein, and TNF tumor necrosis factor.
†  P values are based on global tests to assess heterogeneity among treatment groups. Values for all categorical vari-
ables are based on a two-sided chi-square test or Fisher’s exact test. P values for continuous variables are based on 
analysis of variance of the van der Waerden normal scores.
‡ Race was self-reported.
§ The body-mass index is the weight in kilograms divided by the square of the height in meters.
¶ The normal range for CRP is 0 to 3 mg per liter.
‖ The Mayo score can range from 0 to 12 points, with higher scores indicating more severe disease.
** Immunosuppressant agents include azathioprine, 6-mercaptopurine, and methotrexate.
The New England Journal of Medicine 
Downloaded from nejm.org on March 9, 2021. For personal use only. No other uses without permission. 
 Copyright © 2012 Massachusetts Medical Society. All rights reserved. 
Tofacitinib in Active Ulcer ative Colitis
n engl j med 367;7 nejm.org august 16, 2012 621
(Fig. 1C). Endoscopic remission at 8 weeks oc-
curred in 1 of 48 patients (2%) receiving placebo, 
as compared with 3 of 31 (10%) receiving 0.5 mg 
of tofacitinib (P = 0.14), 6 of 33 (18%) receiving 
0.5 mg of tofacitinib (P = 0.01), 10 of 33 (30%) 
receiving 10 mg of tofacitinib (P<0.001), and 13 of 
49 (27%) receiving 15 mg of tofacitinib (P<0.001) 
(Fig. 1D).
The mean total Mayo scores, mean partial 
Mayo scores, mean Inflammatory Bowel Disease 
Questionnaire scores, mean CRP concentrations, 
and mean fecal calprotectin concentrations dur-
ing the study period are shown in Figure 2 (and 
in Fig. 3 in the Supplementary Appendix).
Safety
The most commonly reported adverse events re-
lated to infection were influenza and nasophar-
yngitis (in six patients each) (Table 2). Two pa-
tients receiving 10 mg of tofacitinib twice daily 
had serious adverse events from infection (post-
operative abscess in one and anal abscess in the 
other). There was a dose-dependent increase in 
both LDL and HDL cholesterol concentrations at 
8 weeks with tofacitinib, which reversed after dis-
continuation of the study drug (Tables 1 and 3 in 
the Supplementary Appendix). During the study 
period, the absolute neutrophil count was less than 
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Figure 1. Rates of Primary and Major Secondary End Points at 8 Weeks in the Modified Intention-to-Treat Population, According to Study 
Group.
The percentages of patients are shown for the primary end point of clinical response at 8 weeks (Panel A) and for the secondary end points 
of clinical remission at 8 weeks (Panel B), endoscopic response at 8 weeks (Panel C), and endoscopic remission at 8 weeks (Panel D). 
The numbers in the bars are the numbers of patients in whom the end point was reached over the total number of patients in the group.
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receiving tofacitinib (one at a dose of 10 mg twice 
daily and two at a dose of 15 mg twice daily); it 
was less than 1000 cells per cubic millimeter in 
none of the patients.
Discussion
In this 8-week phase 2 trial of patients with mod-
erately or severely active ulcerative colitis, in most 
of whom conventional therapy (mesalamine, glu-
cocorticoids, immunosuppressants, or anti-TNF 
agents or a combination thereof) had failed, the 
highest dose of tofacitinib (15 mg twice daily) 
achieved significant improvements in the prima-
ry outcome of induction of a clinical response 
and in the secondary outcomes of clinical remis-
sion and endoscopic response and remission. The 
10-mg twice-daily dose achieved significant im-
provements in most secondary outcomes. In ad-
dition, tofacitinib administration resulted in a 
reduction of CRP and fecal calprotectin concen-
trations and improvements in the Inflammatory 
Bowel Disease Questionnaire score. The efficacy 
of tofacitinib as maintenance therapy for ulcer-
ative colitis is unknown.
We required patients receiving azathioprine, 
6-mercaptopurine, and methotrexate to discon-






























































































































Figure 2. Mean Scores on Clinical Scales and Mean Clinical Concentrations during the 8-Week Study Period, According to Study Group.
The mean total Mayo scores (Panel A), mean Inflammatory Bowel Disease Questionnaire (IBDQ) scores (Panel B), natural log–trans-
formed mean C-reactive protein (CRP) concentrations (Panel C), and natural log–transformed mean fecal calprotectin concentrations 
(Panel D) are shown. P values reflect the difference between each active treatment and placebo in the change from baseline to week 8. 
Mayo scores can range from 0 to 12 (with higher scores indicating more severe disease), and scores on the IBDQ can range from 0 to 
224 (with scores ≥170 indicating clinically inactive disease). The normal range of CRP concentrations is 0 to 3 mg per liter. Last-observa-
tion-carried-forward imputation was used. I bars indicate standard errors.
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with tofacitinib, and patients who had previously 
received anti-TNF therapy were required to dis-
continue it for at least 8 weeks before study en-
try. Thus, the results cannot be extrapolated to 
patients who do not discontinue those agents 
before treatment with tofacitinib. 
In our previous small, 4-week phase 2a trial of 
tofacitinib at doses of 1 mg, 5 mg, and 15 mg twice 
daily in patients with moderate or severe Crohn’s 
disease, there were high rates of response and 
remission and no evidence of significant clinical 
efficacy with tofacitinib.25 Whether the failure of 
tofacitinib for the clinical efficacy end points in 
Crohn’s disease represents a real difference from 
ulcerative colitis in the effect of tofacitinib is 
unclear.
Table 2. Summary of Safety Findings through 12 Weeks, According to Study Group.*
Characteristic
Placebo 









No. of adverse events 46 34 20 37 41
Serious adverse events — no. of patients (%)‡ 4 (8) 1 (3) 1 (3) 2 (6) 2 (4) 0.47
Serious adverse events from infection — no. of  
patients (%)‡
0 0 0 2 (6) 0
Adverse events — no. of patients (%) 23 (48) 19 (61) 11 (33) 14 (42) 20 (41) 0.74
Adverse events occurring in ≥5% of patients in any  
tofacitinib group — no. (%)§
Abdominal pain 1 (2) 1 (3) 0 0 3 (6)
Ulcerative colitis 9 (19) 5 (16) 3 (9) 2 (6) 3 (6)
Dyspepsia 0 2 (6) 1 (3) 0 0
Influenza 3 (6) 2 (6) 0 0 1 (2)
Nasopharyngitis 1 (2) 2 (6) 1 (3) 1 (3) 1 (2)
Sinusitis 0 2 (6) 0 0 0
Arthralgia 0 0 0 2 (6) 2 (4)
Pain in extremity 0 1 (3) 0 2 (6) 0
Dizziness 1 (2) 2 (6) 0 1 (3) 2 (4)
Headache 2 (4) 2 (6) 3 (9) 3 (9) 4 (8)
Rash 0 0 2 (6) 1 (3) 0
Adverse events leading to study-drug discontinuation 
— no. of patients (%)
4 (8) 2 (6) 0 1 (3) 2 (4) 0.37
Adverse events from infection — no. of patients (%) 7 (15) 8 (26) 3 (9) 9 (27) 3 (6) 1.00
Change in LDL cholesterol from baseline — mg/dl¶ −3.5±21.3 10.7±37.8 −0.7±15.6 −5.8±21.8 1.5±19.3
Change in HDL cholesterol from baseline — mg/dl‖ 1.9±10.1 4.5±12.7 3.0±9.9 0.9±15.0 0.9±14.7
* Plus–minus values are means ±SD. Twenty of 31 patients (65%), 26 of 33 (79%), 31 of 33 (94%), and 45 of 49 (92%) 
in the 0.5-mg, 3-mg, 10-mg, and 15-mg tofacitinib groups, respectively, and 35 of 48 patients (73%) in the placebo 
group completed the study and had safety data after 8 weeks, unless otherwise indicated.
† P values are based on Fisher’s exact test for the comparison of the combined tofacitinib groups with placebo group.
‡  The protocol definition of a serious adverse event is any untoward medical occurrence at any dose that results in death, 
is life-threatening (has an immediate risk of death), requires admission to a hospital or prolongation of existing hospi-
talization, results in persistent or significant disability or incapacity, or results in a congenital anomaly or birth defect.
§ See the Supplementary Appendix for an expanded version of this table that includes adverse events occurring in more 
than 1% of patients in any tofacitinib group and clinical laboratory test data.
¶ For low-density lipoprotein (LDL) cholesterol, data at 12 weeks were available for 28 of 31 patients (90%), 28 of 33 
(85%), 30 of 33 (91%), and 47 of 49 (96%) in the 0.5-mg, 3-mg, 10-mg, and 15-mg tofacitinib groups, respectively, and 
for 43 of 48 patients (90%) in the placebo group.
‖ For high-density lipoprotein (HDL) cholesterol, data at 12 weeks were available for 28 of 31 patients (90%), 28 of 33 
(85%), 31 of 33 (94%), and 47 of 49 (96%) in the 0.5-mg, 3-mg, 10-mg, and 15-mg tofacitinib groups, respectively, and 
for 43 of 48 patients (90%) in the placebo group.
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Tofacitinib in Active Ulcer ative Colitis
Tofacitinib treatment resulted in an increase 
in LDL and HDL cholesterol levels; however, the 
small size and short duration of the trial did not 
allow for a comprehensive assessment of the 
safety and tolerability of the drug in patients with 
ulcerative colitis. In patients with rheumatoid ar-
thritis, tofacitinib has been associated with in-
creases in LDL cholesterol and serum creatinine 
concentrations and decreases in the absolute neu-
trophil count; and the 15-mg twice-daily dose has 
been associated with an increased risk of infec-
tion. In the current study, we observed three cases 
in which the absolute neutrophil count decreased 
to less than 1500 per cubic millimeter and a dose-
dependent increase in both LDL and HDL choles-
terol concentrations but not an increase in aspar-
tate aminotransferase, alanine aminotransferase, 
or serum creatinine concentrations or a decrease 
in serum hemoglobin concentration. The mech-
anism for the alterations in cholesterol profile is 
unknown. The clinical consequences of these 
laboratory abnormalities require further study.
In conclusion, patients with moderately or se-
verely active ulcerative colitis treated with tofaci-
tinib had a clinical response and clinical remission 
more frequently than those receiving placebo.
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